JP2022530442A5 - - Google Patents

Info

Publication number
JP2022530442A5
JP2022530442A5 JP2021563165A JP2021563165A JP2022530442A5 JP 2022530442 A5 JP2022530442 A5 JP 2022530442A5 JP 2021563165 A JP2021563165 A JP 2021563165A JP 2021563165 A JP2021563165 A JP 2021563165A JP 2022530442 A5 JP2022530442 A5 JP 2022530442A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
adc
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021563165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029656 external-priority patent/WO2020219774A1/en
Publication of JP2022530442A publication Critical patent/JP2022530442A/ja
Publication of JP2022530442A5 publication Critical patent/JP2022530442A5/ja
Withdrawn legal-status Critical Current

Links

JP2021563165A 2019-04-24 2020-04-23 アントラサイクリン抗体薬物複合体およびその使用 Withdrawn JP2022530442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838267P 2019-04-24 2019-04-24
US62/838,267 2019-04-24
PCT/US2020/029656 WO2020219774A1 (en) 2019-04-24 2020-04-23 Anthracycline antibody-drug conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2022530442A JP2022530442A (ja) 2022-06-29
JP2022530442A5 true JP2022530442A5 (cg-RX-API-DMAC7.html) 2023-05-01

Family

ID=72940981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563165A Withdrawn JP2022530442A (ja) 2019-04-24 2020-04-23 アントラサイクリン抗体薬物複合体およびその使用

Country Status (4)

Country Link
US (1) US20220226493A1 (cg-RX-API-DMAC7.html)
EP (1) EP3959242A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022530442A (cg-RX-API-DMAC7.html)
WO (1) WO2020219774A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
CN120399078B (zh) * 2025-05-08 2026-03-06 上海天泽云泰生物医药股份有限公司 靶向cd117的纳米抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
WO2009126730A2 (en) * 2008-04-09 2009-10-15 The Trustees Of The University Of Pennsylvania Canine single chain fragment variable antibody libraries and uses thereof
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
EP3218400A1 (en) * 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-pdgf-b antibodies and methods of use
HK1256681A1 (zh) * 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
KR20190014525A (ko) * 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
US10111966B2 (en) * 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
US10882915B2 (en) * 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
EP3700568A4 (en) * 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
JP2021526525A (ja) * 2018-06-07 2021-10-07 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 抗体薬物コンジュゲート(adcs)を用いた治療方法
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
AU2019374055B2 (en) * 2018-10-30 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods for allogeneic hematopoietic stem cell transplantation
JP2022530438A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド 抗cd117抗体薬物複合体およびその使用
WO2020219778A2 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
CA3134319A1 (en) * 2019-04-24 2020-10-29 Rahul Palchaudhuri Anti-cd117 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2022530438A5 (cg-RX-API-DMAC7.html)
EP4494657A1 (en) Exatecan derivative-antibody conjugate and medical use thereof
JP2022512778A5 (cg-RX-API-DMAC7.html)
WO2022078260A1 (zh) 一种喜树碱类衍生物及其配体-药物偶联物
US12311030B2 (en) Antibody-sting agonist conjugates and their use in immunotherapy
JP5314590B2 (ja) カンプトテシン結合部分
ES2795818T3 (es) Anticuerpos CD48 y conjugados de los mismos
KR20200017391A (ko) 친수성 링커 및 이의 접합체
JP2022530089A5 (cg-RX-API-DMAC7.html)
ES2307294T3 (es) Anticuerpos monoclonales de raton humanizados anti-cea tipo iii con injertados a cdr.
RU2004135101A (ru) Коньюгаты "производные калихеамицина-носитель"
WO2019170131A1 (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
EP3335734A1 (en) Linker-drug and antibody-drug conjugate (adc) employing the same
IE76467B1 (en) New linker for bioactive agents
JP2009506790A (ja) 毒素とコンジュゲートしたeph受容体抗体
JP2000503639A (ja) 分枝ヒドラゾンのリンカー類
CN107074879A (zh) 应用于细胞结合分子‑药物共轭体的新型细胞毒性分子
JP2025518739A (ja) オリゴ糖リンカー、オリゴ糖リンカーを含むリンカー-ペイロード、および糖鎖がリモデリングされた抗体薬物複合体、その製造方法と使用
JP2023159335A5 (cg-RX-API-DMAC7.html)
EP3165237A1 (en) Antibody-drug conjugate (adc) and method for forming the same
TW202241454A (zh) 抗體-免疫賦活化劑共軛物之新穎製造方法
TWI905962B (zh) 用於綴合之化合物、綴合物及包含其之醫藥組成物
CN120417932A (zh) 接头-有效载荷化合物、偶联物及其应用
EP4442283A1 (en) Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof
KR20230127918A (ko) 신규 항체 약물 접합체